Alembic Pharmaceuticals Ltd. on Thursday, April 16, said it has received final approval from the US Food and Drug Administration (USFDA) for its generic...
Aurobindo Pharma’s wholly owned subsidiary, CuraTeQ Biologics, has reported positive top-line results from the Phase 3 trial of its omalizumab biosimilar, BP11, indicating comparable...